Cephulac

Quick links to important sections

Cephulac

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cephulac

Property Description
Active ingredient Lactulose
Form Oral solution or syrup
Pharmacological class Synthetic Disaccharide Osmotic Laxative
General purpose Supports bowel regulation and metabolic waste clearance
Origin Synthetic, non-absorbable sugar derivative

Cephulac is the trade name for an oral medication containing the active ingredient Lactulose, a synthetic disaccharide osmotic laxative. This medicine is a prescription-only liquid preparation utilized to modify intestinal function and assist in the clearance of specific metabolic waste products. Its identity is rooted in its origin as a manufactured sugar and its non-systemic, localized action within the gastrointestinal tract, a mechanism that is clinically recognized for its efficacy.


What Type of Medicine is Cephulac (Lactulose)?

Cephulac is a specific type of osmotic laxative, a drug class defined by its capacity to draw water into the intestines. The active substance, Lactulose, is a synthetic disaccharide, a molecule derived in a laboratory that the human small intestine lacks the necessary enzymes to digest. This ensures the compound is not absorbed into the body. Unlike stimulant laxatives, which compel bowel contractions, Lactulose achieves its effect through a more passive, physical mechanism involving the movement of water, offering a functionally distinct approach to bowel regulation.


General Purpose and High-Level Action

The general purpose of Cephulac is characterized by a dual therapeutic effect occurring within the colon. Firstly, by leveraging its potent osmotic effect, the medication achieves substantial water retention in the stool, generally helping to support the regularity of bowel movements. Secondly, as the substance is broken down by the resident gut bacteria, it produces acids that facilitate the trapping of ammonia, a key metabolic byproduct, thereby assisting its removal via the gut. This combined activity aids the body in managing both intestinal regularity and the clearance of potentially harmful substances.

Regulatory References

  1. FDA Label for Lactulose

What side effects are possible with Cephulac?

Possible side effects and safety information

The official safety profile for Cephulac (Lactulose) is structured around the adverse reactions documented in regulatory sources such as the EMA Summary of Product Characteristics and FDA DailyMed. This profile is characterized by effects primarily related to the gastrointestinal system.

Frequency-Classified Adverse Reactions

The following frequency classifications are based on regulatory standards:

Classification Adverse Reactions
Very Common (ge 1/10) Diarrhoea
Common (ge 1/100 to <1/10) Flatulence, Abdominal pain, Nausea, Vomiting
Uncommon (ge 1/1,000 to <1/100) Electrolyte imbalance
Not Known Hypersensitivity reactions, Rash, Pruritus, Urticaria

Serious Adverse Reactions and Safety Considerations

The most serious safety concern documented is the potential for electrolyte imbalance (e.g., hypokalemia) resulting from severe, persistent diarrhoea, particularly when high doses are used for long periods, such as in the management of hepatic encephalopathy. Regulatory documents advise that for elderly or debilitated patients receiving long-term treatment (over six months), periodic monitoring of serum electrolytes may be needed.

Time-related patterns show that flatulence and intestinal cramps frequently occur at the start of treatment but are typically transient.

Safety-Related Restrictions

Cephulac is contraindicated and must not be used in individuals with pre-existing conditions including gastrointestinal obstruction, known or suspected digestive perforation, and the metabolic disorder galactosaemia. The use of lactulose with other medicines that cause potassium loss, such as certain diuretics, may increase the risk of hypokalemia.

Overdose and Emergency Response

The official regulatory documentation defines overdosage of Cephulac (Lactulose) primarily by the resulting gastrointestinal distress. Overdose or excessive dosage may lead to documented manifestations such as severe diarrhea, abdominal cramping, and associated nausea or vomiting.

The most serious risks identified in official labeling involve complications arising from this severe fluid loss, resulting in significant Systemic Electrolyte Imbalance. These documented outcomes include the development of hypokalemia (low potassium) and hypernatremia (high sodium). In patients with underlying conditions, severe electrolyte imbalance may potentially result in the exacerbation of Hepatic Encephalopathy.

Regulatory authorities mandate explicit emergency actions. If an overdose is suspected or if severe diarrhea occurs, it is required to seek immediate medical attention or contact a certified Poison Control Center immediately. The officially defined management protocol centers on symptomatic and supportive care, starting with the cessation of treatment and includes the necessary fluid and electrolyte replacement to correct disturbances. Official labeling confirms that no specific antidote is known for Lactulose overdosage. Special considerations are noted for infants, who may be at increased risk for dehydration and hyponatremia following excessive exposure.

Therapeutic Uses of Cephulac

What Cephulac Treats: Main Uses and Benefits

The therapeutic application of Cephulac (Lactulose) is applied across domains where additional symptomatic support is needed: managing chronic issues with intestinal regularity and supporting the central nervous system in the context of severe liver disease. The therapeutic areas for Lactulose include both chronic constipation and the management of portal-systemic encephalopathy.


Relief from Chronic Constipation and Hard Stools

Cephulac is generally applied in clinical settings marked by infrequent bowel movements and the difficult passage of hard, dry stools. It provides supportive therapeutic benefit by addressing this symptom cluster of intestinal irregularity, which can create noticeable physiological strain. The medication contributes to easing the overall symptom load during symptomatic periods and may assist with managing the constipating effects of opioids.

Management of Neurocognitive Symptoms (Hepatic Encephalopathy)

The medication is relevant in conditions characterized by symptoms related to systemic imbalance, specifically in managing the neurological manifestations associated with Hepatic Encephalopathy (HE). It is used in situations involving symptoms related to systemic imbalance, helping to relieve distressing manifestations like confusion, disorientation, and altered mental state. This application offers symptomatic support that may help maintain a sense of stability when symptoms are more noticeable and contributes to easing the overall symptom load related to these manifestations.


Quick Fact: Support for Neurocognitive Symptoms Cephulac is considered relevant in contexts involving heightened systemic burden for managing the distressing symptoms of confusion and altered mental status linked to liver impairment.

Regulatory References

  1. National Institutes of Health (NIH) StatPearls

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The eligibility for Cephulac (Lactulose) is defined by regulatory documents, primarily based on contraindications and specific population considerations.

Classification Restricted Population Status per Regulatory Labeling
Absolute Contraindications Galactosaemia (low-galactose diet) Must not use (due to trace sugars in the formulation).
Gastrointestinal Obstruction Must not use (including digestive perforation or acute inflammatory bowel disease).
Hypersensitivity Must not use (known allergy to the active substance or excipients).
Conditional Use Diabetes Mellitus Use with caution is advised, especially at high doses, due to the potential effect of trace sugars on blood glucose.
Pediatric Population Use is exceptional and requires medical supervision for constipation; safety and efficacy for Hepatic Encephalopathy are not established in the pediatric age group.
Age and Physiological Status Pregnancy and Lactation Generally considered acceptable; no effects are anticipated in the mother or infant due to negligible systemic absorption.

Adults are generally approved for use. For infants and small children, use of the medicine should be managed under strict medical supervision. Elderly patients who receive long-term treatment (over six months) are advised to have their serum electrolytes measured periodically.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Cephulac (Lactulose) focuses on interactions related to its local effect in the colon and its secondary impact on the body's electrolyte balance, rather than systemic metabolic pathways.


Pharmacodynamic and Local Interactions

Co-administration with medicines that increase potassium loss may lead to reinforced effects. Regulatory documents state that agents such as Diuretics (e.g., Thiazides), Corticosteroids, and Amphotericin B may increase the risk of developing hypokalemia (low potassium levels).

This secondary effect is clinically relevant, as potassium deficiency can increase the effect of cardiac glycosides such as Digoxin.

Interactions that alter the colonic environment are also documented. Non-absorbable Antacids may inhibit the required drop in colonic pH, potentially reducing the overall effectiveness of Cephulac.


Restrictions and Population-Specific Cautions

Cephulac is formally contraindicated for patients who are required to follow a strict low-galactose diet, due to the presence of small amounts of related sugars within the solution.

In the management of Hepatic Encephalopathy, the concomitant use of other laxatives must be avoided. This restriction is necessary to prevent interference with the careful dose adjustment required to manage the patient's condition. No mandatory time-separation rules for co-administered medicines are specified in the official prescribing information.

Mechanism of Action

How Cephulac Works

Colonic Metabolism and Bacterial Targets

Cephulac (lactulose) is a non-absorbable synthetic disaccharide that passes intact into the colon. Upon reaching the large intestine, it is metabolized by the indigenous colonic bacterial flora. The primary biological target for this step is the enzymatic activity of the commensal enteric bacteria.

Acid Production and Luminal pH Reduction

This bacterial metabolism results in the production of low molecular weight organic acids, predominantly lactic acid and acetic acid. This action generates protons (H^+), resulting in a consequential reduction in the luminal pH of the colon.

Ammonia Trapping and Excretion Cascade

The lowered luminal pH causes the diffusion of gaseous ammonia ( NH3) from the blood into the colon, where it is subjected to protonation. This chemical process converts the lipophilic, freely diffusible ammonia ( NH3) into the non-absorbable, hydrophilic ammonium ion ( NH4^+). The NH4^+ is osmotically retained in the lumen, facilitating its subsequent excretion in the feces, thereby increasing nitrogen excretion.

Dosage and Administration Information

How Cephulac is Used: Administration Guidelines

Cephulac (Lactulose) is administered according to established clinical protocols, with specific instructions for each approved use. The medicine is available as an oral solution or syrup (typically 10 g of lactulose per 15 mL) and may also be used in acute settings as a rectal enema.


Dosing Regimens for Adults

Indication Starting/Loading Dose Maintenance Dose and Goal
Chronic Constipation 15 to 30 mL (10 to 20 g) once daily. Adjusted up to a maximum of 60 mL (40 g) daily.
Hepatic Encephalopathy (HE) Oral: 30 to 45 mL (20 to 30 g) hourly for rapid effect. Titrated to produce 2 to 3 soft stools per day, typically 30 to 45 mL three to four times daily.
HE (Acute Rectal) 300 mL (200 g) mixed with 700 mL of water or saline for a retention enema. Administered every 4 to 6 hours; oral therapy must be initiated before rectal use is discontinued.

Administration Instructions and Timing

  • Preparation: The oral solution may be taken undiluted or mixed with water, fruit juice, or milk to enhance palatability. The specific dose must be measured using a calibrated device. For once-daily dosing, taking the medicine at the same time each day (e.g., at breakfast) is common practice.
  • Titration: For the HE regimen, the dose is not fixed; it is actively adjusted every 1 to 2 days to achieve the specific goal of 2 to 3 soft stools daily. Continuous, long-term therapy is often indicated for HE prevention, while constipation relief may be short-term.
  • Pediatric Use: Specific initial daily doses are outlined for infants and older children/adolescents with HE, which are also administered in divided doses and titrated to the established goal. Due to negligible systemic absorption, no specific dosage adjustments are required for older adults or patients with renal or hepatic impairment.

Recent Clinical Evidence

Recent Clinical Evidence

Early Research and Data Background

Research has explored the role of Cephulac (lactulose) in managing chronic inflammatory conditions, particularly those involving the liver and digestive system. Initial research investigated the compound's action. These findings served as background information for later clinical studies focusing on its therapeutic uses, such as for hepatic encephalopathy (HE) and chronic constipation.

Clinical Trials and Major Findings

Hepatic Encephalopathy (HE)

In the context of HE, a condition associated with elevated ammonia levels due to liver insufficiency, clinical research primarily assesses Cephulac's ability to manage neurological symptoms. Studies examined the compound's mechanism, which involves it reaching the colon intact where bacteria ferment it, creating an acidic environment. This acidification is thought to convert ammonia ( NH3) into ammonium ions ( NH4^+), trapping the ions for excretion and reducing systemic absorption.

  • Studies assessed measurements related to symptom severity, such as changes based on the West Haven Criteria.
  • Research evaluated whether the compound was associated with a change in the risk of recurrent HE episodes.

Chronic Constipation

For chronic constipation, Cephulac is studied for its osmotic effect. Clinical trials focused on data related to symptoms, including changes in stool frequency and consistency. Short-term trials were conducted to assess these variables in various adult populations.

Safety Data Profile

Clinical studies consistently collected detailed data on adverse events. The most commonly gathered data related to gastrointestinal symptoms, which include gas and bloating. Studies also assessed variables such as quality of life measures in patients receiving the compound. Research findings are available for review with a healthcare provider.

Frequently Asked Questions (FAQ)

Common questions about Cephulac (FAQ)


Q: Is Cephulac considered a natural product, a man-made sugar, or a type of fiber?

Official product information describes Cephulac (Lactulose) as a synthetic disaccharide, meaning it is a man-made sugar molecule. Because the human digestive system cannot absorb it, it acts locally within the colon to produce its effects, functionally distinguishing it from natural products or dietary fibers.


Q: Why does the color of the Cephulac solution sometimes darken, and does this mean it’s expired?

According to regulatory information, a normal darkening of the solution’s color may occur during storage, which is characteristic of sugar solutions and generally does not affect how the medicine works. However, exposure to high temperatures or direct light can cause extreme darkening or cloudiness, and solution that appears this way is not recommended for use.


Q: What is the goal for the frequency of bowel movements when taking Cephulac for a liver condition?

When used for the management of the severe liver condition, the medicine’s dosage is adjusted by a healthcare provider to achieve a specific goal: two to three soft stools daily. This specific frequency aligns with the treatment goal of assisting the body in reducing its levels of potentially harmful substances.


Q: Can Cephulac be taken to prevent future episodes of a severe liver-related condition?

Official information indicates that for the management of the chronic liver condition, continuous, long-term therapy with Cephulac is often prescribed. The aim of this continuous use is described as helping to lessen the severity of the condition and assisting in reducing the risk of recurrence of future episodes.


Q: How long does it typically take for Cephulac to produce a bowel movement?

Regulatory information indicates that because the medicine must pass intact through the digestive system to reach the colon, it may require 24 to 48 hours to produce the desired bowel movement. The onset of effect is not immediate.


Q: What is the general information provided about what to do if a dose of Cephulac is forgotten?

If a dose is forgotten, general patient advice is to skip the missed dose and continue with the next scheduled dose at the usual time. Double doses are typically not recommended to compensate for a forgotten one.


Q: How often is the dose of Cephulac usually adjusted by a healthcare provider?

For the severe liver condition regimen, regulatory documents state that the dosage may be adjusted by a healthcare provider every day or two until the treatment goals are met. For chronic constipation, dose changes are made if needed, but the frequency of adjustment is not strictly defined in the same way.


Q: Do the effects of Cephulac change over time, requiring less or more of the medicine?

Official documentation does not specify whether the effectiveness of the medicine changes significantly over time or if tolerance develops. However, continuous therapy is indicated for the chronic liver condition.


Q: Can Cephulac lead to a chemical imbalance in the body, such as low potassium?

Official product information states that taking excessive doses can result in persistent diarrhea. This can lead to complications such as fluid loss and hypokalemia (abnormally low potassium), which is a key safety consideration mentioned in regulatory documents.


Q: What are the signs of potential dehydration associated with taking Cephulac?

Regulatory and health authority sources indicate that signs of dehydration—which may result from severe diarrhea—can include increased thirst, a dry mouth, dizziness, or a noticeable decrease in urine output.


Q: What is the general advice for managing mild stomach discomfort or cramping from Cephulac?

Initial flatulence and stomach cramps are common and usually temporary. Regulatory information does not provide specific instructions for managing these mild symptoms, but they are often transient.


Q: What constitutes a serious or severe side effect that requires immediate attention?

Official guidance indicates that severe, persistent diarrhea or vomiting, especially when accompanied by signs of a severe electrolyte problem, requires prompt medical review. These signs may include a fast or irregular heartbeat, severe muscle cramps, or confusion.


Q: Is it true that taking Cephulac can sometimes be associated with muscle cramps or weakness?

The safety profile derived from regulatory data lists muscle pain, cramps, or twitching as possible, though uncommon, side effects. These symptoms are often associated with a disturbance of key electrolytes.


Q: Why is a person scheduled for a colonoscopy advised to stop taking Cephulac beforehand?

Official warnings mention a potential theoretical risk related to the accumulation of certain gases, such as hydrogen gas, in the colon. In rare instances, this accumulation could create a risk of reaction during procedures like colonoscopy that use electrocautery.


Q: Is there a described interaction between Cephulac and the oral contraceptive pill?

Regulatory sources generally do not list a formal drug-drug interaction with the oral contraceptive pill. However, if a patient experiences severe diarrhea for more than 24 hours, the efficacy of oral contraceptives could be affected. Further guidance may be discussed with a healthcare provider.


Q: Does having a history of diabetes mean Cephulac is strictly forbidden?

The medicine is not strictly forbidden for individuals with diabetes, but official documents advise using it with caution. This warning is related to the trace amounts of sugars (e.g., galactose) present in the solution, which is a factor to be discussed with a healthcare provider, particularly concerning higher doses.


Q: What is the safety information regarding the use of Cephulac in pediatric populations?

Safety and effectiveness have not been established by the FDA for children. Use for infants and small children, even for constipation, is regarded as exceptional and is typically managed under the supervision of a medical professional. The initial dose should be promptly reduced if diarrhea occurs.


Q: Can taking too much Cephulac cause symptoms other than diarrhea?

Official information regarding overdosage indicates that the primary symptoms are expected to be diarrhea and abdominal cramps. However, excessive dosing may also lead to complications like a loss of body fluids and a serious electrolyte imbalance.


Q: Does taking herbal supplements or vitamins affect the activity of Cephulac?

Regulatory sources generally state that there are no known problems mixing lactulose with most common herbal remedies or vitamins. It is customary to provide a list of all supplements being taken to a healthcare provider.


Q: Are there any known food or drink restrictions while undergoing treatment with Cephulac?

There are no specific food restrictions listed in the official documents. Patients are generally advised to drink sufficient fluids daily (such as 6 to 8 glasses) while on treatment.

How should Cephulac be stored and disposed of?

Cephulac (lactulose solution) must be stored at Controlled Room Temperature, specifically between 20°C and 25°C. The medication must not be frozen and should be protected from temperatures exceeding 30°C, as well as prolonged exposure to direct light. If the solution develops extreme darkening or turbidity due to improper storage, it must not be used.

The container must be kept tightly closed with a child-resistant closure and stored out of the reach of children. Unused or expired Cephulac must not be flushed down a toilet or poured down a sink. Disposal should follow local regulations or use the household trash method, which involves mixing the medicine with an undesirable substance and sealing it before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cephulac found in:

A-Z Index: